Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

• Status: Not yet recruiting
• Trial end date: 2024-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pennsylvania
• Collaborator: Novartis

Criteria

Inclusion Criteria:

• Active psoriatic nail disease defined as a Minimum 4 or more fingernails OR NAPSI>20

• Active skin psoriasis currently (no minimum PASI or BSA) or skin psoriasis in the past documented by a dermatologist

• Age 18-85

Exclusion Criteria:

• History of IL-17 inhibitor use (other therapies including TNF inhibitors or non- biologics DMARDS in the past are acceptable)

• Inflammatory bowel disease

• Metal implants or other concerns for use of MRI

• Active infection

• Patients may have a history of self-reported psoriatic arthritis but may not have active PsA at the time of screening.

• We will exclude patients with onychomyosis of the fingernails on clippings